Literature DB >> 21982859

Introduction of misoprostol for prevention of postpartum hemorrhage at the community level in Senegal.

Mohamed Diadhiou1, Thierno Dieng, Christine Ortiz, Ibrahima Mall, Demba Dione, Nancy L Sloan.   

Abstract

OBJECTIVE: To demonstrate that training ensures correct administration of oral misoprostol by auxiliary midwives for prevention of postpartum hemorrhage (PPH) among women giving birth at the community level in Senegal.
METHODS: A 6-day training program for auxiliary midwives and supervisors, including 1 day of PPH prevention training and a practicum of 10 deliveries at health centers and 3 deliveries at maternity huts, was conducted in 2 Senegalese districts in June-July 2009. Data were collected between July and December 2009 on the administration of oral misoprostol by trained auxiliary midwives among 245 women giving birth at health centers, health posts, and maternity huts.
RESULTS: All participating women received the correct administration of oral misoprostol; however, few women delivering in the community-based maternity huts received the supervision that is locally required to administer misoprostol. Women were willing to pay for some or all of the costs of misoprostol for PPH prevention.
CONCLUSION: Timely management of PPH is essential to reduce maternal mortality. With limited training, auxiliary midwives achieved the correct administration of oral misoprostol that can attain this goal. Community delivery supervised by a skilled attendant limits access to, and need not be a requirement for, PPH prevention.
Copyright © 2011 International Federation of Gynecology and Obstetrics. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21982859     DOI: 10.1016/j.ijgo.2011.08.002

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  7 in total

1.  Cost-effectiveness of two interventions for the prevention of postpartum hemorrhage in Senegal.

Authors:  Michael Vlassoff; Alioune Diallo; Jesse Philbin; Kathryn Kost; Akin Bankole
Journal:  Int J Gynaecol Obstet       Date:  2016-02-12       Impact factor: 3.561

2.  Implementing at-scale, community-based distribution of misoprostol tablets to mothers in the third stage of labor for the prevention of postpartum haemorrhage in Sokoto State, Nigeria: Early results and lessons learned.

Authors:  Nosakhare Orobaton; Jumare Abdulazeez; Dele Abegunde; Kamil Shoretire; Abubakar Maishanu; Nnenna Ikoro; Bolaji Fapohunda; Wapada Balami; Katherine Beal; Akeem Ganiyu; Ringpon Gwamzhi; Anne Austin
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

Review 3.  Task shifting in active management of the third stage of labor: a systematic review.

Authors:  Tessa M Raams; Joyce L Browne; Verena J M M Festen-Schrier; Kerstin Klipstein-Grobusch; Marcus J Rijken
Journal:  BMC Pregnancy Childbirth       Date:  2018-02-06       Impact factor: 3.007

4.  "My job is to get pregnant women to the hospital": a qualitative study of the role of traditional birth attendants in the distribution of misoprostol to prevent post-partum haemorrhage in two provinces in Mozambique.

Authors:  Karen Hobday; Jennifer Hulme; Caroline Homer; Páscoa Zualo Wate; Suzanne Belton; Ndola Prata
Journal:  Reprod Health       Date:  2018-10-16       Impact factor: 3.223

5.  A Stalled Revolution? Misoprostol and the Pharmaceuticalization of Reproductive Health in Francophone Africa.

Authors:  Siri Suh
Journal:  Front Sociol       Date:  2021-04-12

Review 6.  Advancing maternal survival in the global context: are our strategies working?

Authors:  Omar A Khan; Richard Derman; Nancy L Sloan
Journal:  BMC Public Health       Date:  2013-07-29       Impact factor: 3.295

7.  Knowledge and provision of misoprostol among pharmacy workers in Senegal: a cross sectional study.

Authors:  Kate Reiss; Katharine Footman; Eva Burke; Nafissatou Diop; Ramatoulaye Ndao; Babacar Mane; Maaike van Min; Thoai D Ngo
Journal:  BMC Pregnancy Childbirth       Date:  2017-07-03       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.